MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.